These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 27753692)

  • 1. Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.
    Degenhardt F; Dirmeier A; Lopez R; Lang S; Kunst C; Roggenbuck D; Reinhold D; Szymczak S; Rogler G; Klebl F; Franke A; Rieder F
    Inflamm Bowel Dis; 2016 Nov; 22(11):2648-2657. PubMed ID: 27753692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.
    Bogdanos DP; Roggenbuck D; Reinhold D; Wex T; Pavlidis P; von Arnim U; Malfertheiner P; Forbes A; Conrad K; Laass MW
    BMC Gastroenterol; 2012 Aug; 12():102. PubMed ID: 22866900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease.
    Röber N; Noß L; Goihl A; Reinhold D; Jahn J; de Laffolie J; Johannes W; Flemming GM; Roggenbuck D; Conrad K; Laass MW
    Inflamm Bowel Dis; 2017 Sep; 23(9):1624-1636. PubMed ID: 28691939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch.
    Cummings D; Cruise M; Lopez R; Roggenbuck D; Jairath V; Wang Y; Shen B; Rieder F
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1251-1259. PubMed ID: 30411391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential diagnosis of Crohn's disease using antibodies to glycoprotein 2 and Saccharomyces cerevisiae.
    Duman AE; Hülagü S; Çelebi A; Korkmaz U; Musul MM; Şentürk Ö; Şirin G; Yılmaz H; Koç DÖ; Dindar G; Öztürkler M; Bozkurt N; Kır HM
    Turk J Gastroenterol; 2019 Jan; 30(1):21-27. PubMed ID: 30465525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.
    Zhang S; Wu Z; Luo J; Ding X; Hu C; Li P; Deng C; Zhang F; Qian J; Li Y
    Medicine (Baltimore); 2015 Oct; 94(42):e1654. PubMed ID: 26496271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
    Papp M; Sipeki N; Tornai T; Altorjay I; Norman GL; Shums Z; Roggenbuck D; Fechner K; Stöcker W; Antal-Szalmas P; Veres G; Lakatos PL
    J Crohns Colitis; 2015 Aug; 9(8):659-68. PubMed ID: 25968583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch.
    Werner L; Sturm A; Roggenbuck D; Yahav L; Zion T; Meirowithz E; Ofer A; Guzner-Gur H; Tulchinsky H; Dotan I
    J Crohns Colitis; 2013 Dec; 7(11):e522-32. PubMed ID: 23639628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.
    Roggenbuck D; Reinhold D; Wex T; Goihl A; von Arnim U; Malfertheiner P; Büttner T; Porstmann T; Porstmann S; Liedvogel B; Bogdanos DP; Laass MW; Conrad K
    Clin Chim Acta; 2011 Apr; 412(9-10):718-24. PubMed ID: 21195704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
    Sipeki N; Davida L; Palyu E; Altorjay I; Harsfalvi J; Szalmas PA; Szabo Z; Veres G; Shums Z; Norman GL; Lakatos PL; Papp M
    World J Gastroenterol; 2015 Jun; 21(22):6952-64. PubMed ID: 26078573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.
    Caneparo V; Pastorelli L; Pisani LF; Bruni B; Prodam F; Boldorini R; Roggenbuck D; Vecchi M; Landolfo S; Gariglio M; De Andrea M
    Inflamm Bowel Dis; 2016 Dec; 22(12):2977-2987. PubMed ID: 27636380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases.
    Saibeni S; Folli C; de Franchis R; Borsi G; Vecchi M
    Dig Liver Dis; 2003 Dec; 35(12):862-8. PubMed ID: 14703881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies Against Glycoprotein 2 Are Specific Biomarkers for Pediatric Crohn's Disease.
    Shpoliansky M; Roggenbuck D; Pinsker M; Salamon N; Weiss B; Shouval DS; Werner L
    Dig Dis Sci; 2021 Aug; 66(8):2619-2626. PubMed ID: 32886311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies.
    Pavlidis P; Komorowski L; Teegen B; Liaskos C; Koutsoumpas AL; Smyk DS; Perricone C; Mytilinaiou MG; Stocker W; Forbes A; Bogdanos DP
    Clin Chem Lab Med; 2016 Feb; 54(2):249-56. PubMed ID: 26351932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.
    Michaels MA; Jendrek ST; Korf T; Nitzsche T; Teegen B; Komorowski L; Derer S; Schröder T; Baer F; Lehnert H; Büning J; Fellerman K; Sina C
    Inflamm Bowel Dis; 2015 Dec; 21(12):2864-72. PubMed ID: 26273818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations.
    Walker LJ; Aldhous MC; Drummond HE; Smith BR; Nimmo ER; Arnott ID; Satsangi J
    Clin Exp Immunol; 2004 Mar; 135(3):490-6. PubMed ID: 15008984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher titers of anti-Saccharomyces cerevisiae antibodies IgA and IgG are associated with more aggressive phenotypes in Romanian patients with Crohn's disease.
    Gologan S; Iacob R; Preda C; Vadan R; Cotruta B; Catuneanu AM; Iacob S; Constantinescu I; Gheorghe L; Iobagiu S; Gheorghe C; Diculescu M
    J Gastrointestin Liver Dis; 2012 Mar; 21(1):39-44. PubMed ID: 22457858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease.
    Klebl FH; Bataille F; Hofstädter F; Herfarth H; Schölmerich J; Rogler G
    Int J Colorectal Dis; 2004 Jul; 19(4):319-24. PubMed ID: 14745572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA.
    Pavlidis P; Shums Z; Koutsoumpas AL; Milo J; Papp M; Umemura T; Lakatos PL; Smyk DS; Bogdanos DP; Forbes A; Norman GL
    Clin Chim Acta; 2015 Feb; 441():176-81. PubMed ID: 25512163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
    Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A
    Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.